Literature DB >> 18784821

Gene expression profiles associated with advanced pancreatic cancer.

Domenico Campagna1, Leslie Cope, Sindhu S Lakkur, Clark Henderson, Daniel Laheru, Christine A Iacobuzio-Donahue.   

Abstract

Few studies have addressed the expression profiles associated with progression of pancreatic cancer to advanced disease. Towards this end, we performed expression profiling of a series of normal pancreas, pancreatitis and cancer tissues representing early stage resected pancreatic cancers (stages pT2/T3), late stage unresectable cancers (stage pT4) and matched metastases to a variety of organ sites. Microarray data was analyzed using linear modeling of microarray data (LIMMA), and differentially expressed genes were subjected to Gene Set Enrichment Analysis (GSEA). While robust differences were found in primary cancers as compared to normal pancreatic tissues, no differences were found between primary cancers and metastases, whether using matched or unmatched samples. When resected pancreatic cancers were specifically compared to advanced pancreatic cancers, significant differences in gene expression were found associated with growth at the primary site. These differentially expressed genes were most prominent in gene classes that related to MAPK and Wnt pathway, metabolism, immune regulation, cell-cell and cell-matrix interactions within the infiltrating carcinoma. One candidate upregulated gene (MXI1) was validated as having increased expression in advanced stage (T4) carcinomas by real-time PCR (p<0.05) and immunolabeling (p<0.003). We conclude that in addition to the robust changes in expression that accompany pancreatic carcinogenesis additional specific changes occur in association with growth at the primary site. By contrast, metastatic spread is not accompanied by reproducible changes in gene expression. These findings add to our understanding of pancreatic cancer and offer new topics for investigation into the aggressive nature of this deadly tumor type.

Entities:  

Keywords:  MAP kinase; MAX-interacting protein 1; autopsy; c-Myc; carcinoma; metastasis; microarray; oncogene; pancreas

Year:  2008        PMID: 18784821      PMCID: PMC2480531     

Source DB:  PubMed          Journal:  Int J Clin Exp Pathol        ISSN: 1936-2625


  60 in total

1.  Smad4 is dispensable for normal pancreas development yet critical in progression and tumor biology of pancreas cancer.

Authors:  Nabeel Bardeesy; Kuang-Hung Cheng; Justin H Berger; Gerald C Chu; Jessica Pahler; Peter Olson; Aram F Hezel; James Horner; Gregory Y Lauwers; Douglas Hanahan; Ronald A DePinho
Journal:  Genes Dev       Date:  2006-11-15       Impact factor: 11.361

2.  Aggressive pancreatic ductal adenocarcinoma in mice caused by pancreas-specific blockade of transforming growth factor-beta signaling in cooperation with active Kras expression.

Authors:  Hideaki Ijichi; Anna Chytil; Agnieszka E Gorska; Mary E Aakre; Yoshio Fujitani; Shuko Fujitani; Christopher V E Wright; Harold L Moses
Journal:  Genes Dev       Date:  2006-11-15       Impact factor: 11.361

Review 3.  The MAX-interacting transcription factor network.

Authors:  Peter J Hurlin; Jie Huang
Journal:  Semin Cancer Biol       Date:  2006-07-14       Impact factor: 15.707

4.  Patterns of EphA2 protein expression in primary and metastatic pancreatic carcinoma and correlation with genetic status.

Authors:  Shiyama V Mudali; Baojin Fu; Sindhu S Lakkur; Mingde Luo; Erlinda E Embuscado; Christine A Iacobuzio-Donahue
Journal:  Clin Exp Metastasis       Date:  2006-12-05       Impact factor: 5.150

Review 5.  The c-Myc target gene network.

Authors:  Chi V Dang; Kathryn A O'Donnell; Karen I Zeller; Tam Nguyen; Rebecca C Osthus; Feng Li
Journal:  Semin Cancer Biol       Date:  2006-07-25       Impact factor: 15.707

6.  RNA interference suppression of MUC1 reduces the growth rate and metastatic phenotype of human pancreatic cancer cells.

Authors:  Hideaki Tsutsumida; Benjamin J Swanson; Pankaj K Singh; Thomas C Caffrey; Shinichi Kitajima; Masamichi Goto; Suguru Yonezawa; Michael A Hollingsworth
Journal:  Clin Cancer Res       Date:  2006-05-15       Impact factor: 12.531

7.  Integrin-linked kinase activity is associated with interleukin-1 alpha-induced progressive behavior of pancreatic cancer and poor patient survival.

Authors:  H Sawai; Y Okada; H Funahashi; Y Matsuo; H Takahashi; H Takeyama; T Manabe
Journal:  Oncogene       Date:  2006-01-16       Impact factor: 9.867

8.  Cancer statistics, 2007.

Authors:  Ahmedin Jemal; Rebecca Siegel; Elizabeth Ward; Taylor Murray; Jiaquan Xu; Michael J Thun
Journal:  CA Cancer J Clin       Date:  2007 Jan-Feb       Impact factor: 508.702

9.  Effects of bone sialoprotein on pancreatic cancer cell growth, invasion and metastasis.

Authors:  Hany Kayed; Jörg Kleeff; Shereen Keleg; Klaus Felix; Thomas Giese; Martin R Berger; Markus W Büchler; Helmut Friess
Journal:  Cancer Lett       Date:  2006-02-20       Impact factor: 8.679

10.  Frequent hypomethylation of multiple genes overexpressed in pancreatic ductal adenocarcinoma.

Authors:  Norihiro Sato; Anirban Maitra; Noriyoshi Fukushima; N Tjarda van Heek; Hiroyuki Matsubayashi; Christine A Iacobuzio-Donahue; Christophe Rosty; Michael Goggins
Journal:  Cancer Res       Date:  2003-07-15       Impact factor: 12.701

View more
  9 in total

1.  Oncolytic virotherapy with human telomerase reverse transcriptase promoter regulation enhances cytotoxic effects against gastric cancer.

Authors:  Tomoya Kato; Mikihito Nakamori; Shuichi Matsumura; Masaki Nakamura; Toshiyasu Ojima; Hiroshi Fukuhara; Yasushi Ino; Tomoki Todo; Hiroki Yamaue
Journal:  Oncol Lett       Date:  2021-04-23       Impact factor: 2.967

2.  DPEP1 inhibits tumor cell invasiveness, enhances chemosensitivity and predicts clinical outcome in pancreatic ductal adenocarcinoma.

Authors:  Geng Zhang; Aaron Schetter; Peijun He; Naotake Funamizu; Jochen Gaedcke; B Michael Ghadimi; Thomas Ried; Raffit Hassan; Harris G Yfantis; Dong H Lee; Curtis Lacy; Anirban Maitra; Nader Hanna; H Richard Alexander; S Perwez Hussain
Journal:  PLoS One       Date:  2012-02-20       Impact factor: 3.240

3.  Long noncoding intronic RNAs are differentially expressed in primary and metastatic pancreatic cancer.

Authors:  Ana C Tahira; Márcia S Kubrusly; Michele F Faria; Bianca Dazzani; Rogério S Fonseca; Vinicius Maracaja-Coutinho; Sergio Verjovski-Almeida; Marcel C C Machado; Eduardo M Reis
Journal:  Mol Cancer       Date:  2011-11-13       Impact factor: 27.401

Review 4.  Noncoding RNAs as potential biomarkers to predict the outcome in pancreatic cancer.

Authors:  Kaizhou Jin; Guopei Luo; Zhiwen Xiao; Zuqiang Liu; Chen Liu; Shunrong Ji; Jin Xu; Liang Liu; Jiang Long; Quanxing Ni; Xianjun Yu
Journal:  Drug Des Devel Ther       Date:  2015-02-26       Impact factor: 4.162

5.  RNA sequencing analyses reveal novel differentially expressed genes and pathways in pancreatic cancer.

Authors:  Yixiang Mao; Jianjun Shen; Yue Lu; Kevin Lin; Huamin Wang; Yanan Li; Ping Chang; Mary G Walker; Donghui Li
Journal:  Oncotarget       Date:  2017-06-27

6.  Identification of molecular biomarkers for pancreatic cancer with mRMR shortest path method.

Authors:  Shuhua Shen; Tuantuan Gui; Chengcheng Ma
Journal:  Oncotarget       Date:  2017-06-20

7.  S100P is a metastasis-associated gene that facilitates transendothelial migration of pancreatic cancer cells.

Authors:  Sayka Barry; Claude Chelala; Kate Lines; Makoto Sunamura; Amu Wang; Federica M Marelli-Berg; Caroline Brennan; Nicholas R Lemoine; Tatjana Crnogorac-Jurcevic
Journal:  Clin Exp Metastasis       Date:  2012-09-25       Impact factor: 5.150

8.  Molecular markers associated with outcome and metastasis in human pancreatic cancer.

Authors:  Anke Van den Broeck; Hugo Vankelecom; Rudy Van Eijsden; Olivier Govaere; Baki Topal
Journal:  J Exp Clin Cancer Res       Date:  2012-08-27

9.  Integrated transcriptome meta-analysis of pancreatic ductal adenocarcinoma and matched adjacent pancreatic tissues.

Authors:  Sevcan Atay
Journal:  PeerJ       Date:  2020-10-27       Impact factor: 2.984

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.